The medical community is buzzing with anticipation surrounding retatrutide, a new dual GIP and GLP-1 receptor that’s exhibiting significant potential in clinical trials for treating obesity. Unlike some existing weight loss approaches, retatrutide appears to provide a more substantial decrease in body mass and improve metabolic markers, particula